ArticleVaccine2012
Oral vaccination with inactivated influenza vaccine induces cross-protective immunity.
Article in Vaccine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 31 citations in OpenAlex.
- Mucosal delivery of influenza antigens using a replication deficient adenovirus supports broadly reactive antibody responses and heterologous viral immunity in the respiratory tract of animals.bioRxiv : the preprint server for biology · 2025Article
- Article
- A path toward developing a universal mucosal influenza vaccine: An upside-down influenza HA vaccine based on extracellular vesicles.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Influenza Virus Inactivated by Heavy Ion Beam Irradiation Stimulates Antigen-Specific Immune Responses.Pharmaceutics · 2024Article
- Article
- An alternative to airborne droplet transmission route of SARS-CoV-2, the feco-oral route, as a factor shaping COVID-19 pandemic.Medical hypotheses · 2022Article
- Sublingual Vaccination with Live Influenza Virus Induces Better Protection Than Oral Immunization in Mice.Life (Basel, Switzerland) · 2022Article
- Yeasts in nanotechnology-enabled oral vaccine and gene delivery.Bioengineered · 2021Review
- Oral Delivery of Novel RecombinantVaccines · 2021Article
- Passive Immunity and Antibody Response Induced byVaccines · 2021Article
- Article
- Influenza Virus-Like Particles Presenting bothPharmaceutics · 2019Article
- Distal Consequences of Oral Inflammation.Frontiers in immunology · 2019Review
- Transmission of SARS and MERS coronaviruses and influenza virus in healthcare settings: the possible role of dry surface contamination.The Journal of hospital infection · 2016Review
- Prospects of HA-based universal influenza vaccine.BioMed research international · 2015Review
- Immunogenicity of an electron beam inactivated Rhodococcus equi vaccine in neonatal foals.PloS one · 2014Article
- Effects of administration of live or inactivated virulent Rhodococccus equi and age on the fecal microbiome of neonatal foals.PloS one · 2013Article
- Immunogenicity and protection of oral influenza vaccines formulated into microparticles.Journal of pharmaceutical sciences · 2012Article
- Microneedle and mucosal delivery of influenza vaccines.Expert review of vaccines · 2012Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Oral vaccination would provide an easy and safe measure to prevent infectious diseases by facilitating mass immunization. We investigated the feasibility of oral vaccination with inactivated whole influenza virus (A/PR8/34). Oral vaccination of mice induced high levels of serum IgG and IgA antibodies specific to the homologous virus (A/PR8) as well as cross reactive to heterologous (A/California/04/09) and heterosubtypic viruses (A/Philippines/2/82). IgG1 isotype antibodies were found to be induced at significantly higher levels than IgG2a antibodies. These antibodies induced by oral vaccination exhibited hemagglutination inhibition activities. High levels of both IgG and IgA antibodies were induced in vagina and lungs. Mucosal IgA antibodies were also elicited in other sites including saliva, urine, and fecal samples. Orally vaccinated mice were completely protected against challenge with homologous or heterologous viruses, and partially protected against heterosubtypic virus. Importantly, high recall antibody secreting cell (ASC) responses were induced in spleen, indicating the generation of memory B cells by oral vaccination. The present study therefore presents new findings of cross-reactive antibodies at systemic and diverse mucosal sites, recall antibody responses, and cross-protective efficacies by oral vaccination, thus supporting a proof-of-concept that oral delivery of vaccines can be developed as an effective vaccination route.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.